Success Metrics

Clinical Success Rate
100.0%

Based on 12 completed trials

Completion Rate
100%(12/12)
Active Trials
0(0%)
Results Posted
58%(7 trials)

Phase Distribution

Ph phase_1
6
50%
Ph phase_2
6
50%

Phase Distribution

6

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
6(50.0%)
Phase 2Efficacy & side effects
6(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

12 of 12 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(12)

Detailed Status

Completed12

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 16 (50.0%)
Phase 26 (50.0%)

Trials by Status

completed12100%

Recent Activity

0 active trials
Showing 5 of 12
completedphase_2

A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.

NCT03555994
completedphase_2

A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes Mellitus

NCT03596177
completedphase_1

A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese Participants

NCT03625778
completedphase_2

A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

NCT03745937
completedphase_2

A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well Tolerated

NCT03550378
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT03555994Phase 2

A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.

Completed
NCT03596177Phase 2

A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes Mellitus

Completed
NCT03625778Phase 1

A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese Participants

Completed
NCT03745937Phase 2

A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

Completed
NCT03550378Phase 2

A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well Tolerated

Completed
NCT03444584Phase 2

Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes

Completed
NCT03244800Phase 2

A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.

Completed
NCT03385369Phase 1

A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent

Completed
NCT02548585Phase 1

A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

Completed
NCT03235375Phase 1

A Study to Evaluate Pharmacokinetics, Safety and Tolerability of MEDI0382 in Renal Impairment Subjects

Completed
NCT03347968Phase 1

Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382

Completed
NCT02394314Phase 1

A Phase 1, Single Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy Volunteers

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12